<p>Immuneering Corporation (NASDAQ:IMRX - 获取免费报告) 在 12 月份的空头头寸大幅增长。截至 12 月 31 日，空头头寸总计为 10,924,303 股，比 12 月 15 日的 7635854 股增长了 43.1%。该公司的约 21.9% 的股份被做空。根据平均每日交易量 1,780,211 股，目前的空头头寸比率为 6.1 天。</p>
<h2>华尔街分析师观点</h2>
<p>一些股票研究分析师最近对该公司发表了看法。HC Wainwright 在 9 月 30 日的研究报告中重申了 “买入” 评级，并将 Immuneering 的目标价格设定为 11.00 美元。Leerink Partners 在 10 月 31 日的报告中将 Immuneering 的评级提升至 “强力买入”。Chardan Capital 在 11 月 13 日的研究报告中重申了 “买入” 评级，并将 Immuneering 的目标价格设定为 20.00 美元。瑞穗证券在 10 月 29 日的研究报告中将 Immuneering 的目标价格设定为 12.00 美元。最后，Weiss Ratings 在 12 月 29 日的研究报告中重申了对 Immuneering 的 “卖出（d-）” 评级。一位分析师给予该股票 “强力买入” 评级，六位分析师给予 “买入” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，该公司的共识评级为 “适度买入”，共识目标价格为 16.50 美元。</p>
<p><strong>查看我们最新的 Immuneering 股票报告</strong></p>
<h2>Immuneering 股价下跌 1.3%</h2>
<p>IMRX 股票在周五交易中下跌 0.06 美元，报 4.58 美元。该股票交易了 1,571,991 股，而其平均交易量为 3,135,325 股。该公司的市值为 2.9573 亿美元，市盈率为-2.57，贝塔值为 0.48。Immuneering 的股价在过去一年中最低为 1.10 美元，最高为 10.08 美元。该公司的 50 日简单移动平均为 6.37 美元，200 日简单移动平均为 5.78 美元。</p>
<p>Immuneering (NASDAQ:IMRX - 获取免费报告) 最近在 11 月 12 日发布了季度财报。该公司报告每股收益为-0.38 美元，低于共识预期的-0.37 美元，差距为 0.01 美元。整体来看，分析师预测 Immuneering 在当前财政年度的每股收益为-1.86 美元。</p>
<h2>Immuneering 的内部交易</h2>
<p>在相关消息中，董事 Peter Feinberg 在 1 月 12 日的交易中购买了 20,000 股该公司的股票。每股平均购买价格为 4.35 美元，总交易额为 87,000.00 美元。收购后，该董事在公司中持有 135,441 股，价值 589,168.35 美元。此交易代表其持股比例增加了 17.32%。该交易已在证券交易委员会的法律文件中披露，可通过 SEC 网站访问。在上个季度，内部人士购买了价值 108,400 美元的 24,924 股公司股票。公司内部人士持有该公司 22.90% 的股份。</p>
<h2>Immuneering 的机构交易</h2>
<p>大型投资者最近对该公司的持仓进行了调整。赛诺菲在第三季度以 18,960,000 美元的估值收购了 Immuneering 的新股份。先锋集团在第三季度将其在 Immuneering 的持股增加了 128.5%。先锋集团目前拥有 2,415,244 股该公司的股票，价值 16,907,000 美元，此前在上个季度购买了 1,358,322 股。Citadel Advisors LLC 在第三季度以约 6,602,000 美元的估值收购了 Immuneering 的新股份。Blue Owl Capital Holdings LP 在第三季度以约 3,850,000 美元的估值购买了 Immuneering 的新股份。最后，Monashee Investment Management LLC 在第三季度以约 2,100,000 美元的估值收购了 Immuneering 的新股份。机构投资者持有该公司 67.65% 的股份。</p>
<h2>Immuneering 公司简介</h2>
<p>(获取免费报告)</p>
<p>Immuneering Nasdaq: IMRX 是一家临床阶段的生物制药公司，利用人工智能和其专有的 RABIT（重新利用和加速生物技术工具）平台设计和优化小分子和肽类疗法。通过分析大规模生物医学数据集，Immuneering 的机器学习算法识别新型药物 - 靶点相互作用，重新利用现有药物框架并加速候选药物的选择。该公司的人工智能驱动方法旨在缩短开发时间并改善在高未满足医疗需求领域的治疗效果。</p>
<p>该公司的主导项目 IRX-2 是一种小分子候选药物，目前正在进行针对疼痛性糖尿病周围神经病的第二阶段临床试验。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Immuneering</li>
<li>Elon 将 SpaceX 上市！100 美元的首次公开募股机会！</li>
<li>家族信托如何帮助保护您的财富</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>执行命令 14330：特朗普最大的一次</li>
<li>新法律：国会批准数字美元的设立？</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1,000 美元在 Immuneering 吗？</h2>
<p>在您考虑 Immuneering 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Immuneering 并不在名单上。</p>
<p>尽管 Immuneering 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

IMRX

<p>Immuneering Corporation（纳斯达克代码：IMRX）在短期空头头寸方面经历了显著增长，12 月份上涨了 43.1%，达到 10,924,303 股。约 21.9% 的股票被做空，覆盖天数比率为 6.1 天。分析师的评级各不相同，其中有一项强烈买入、六项买入和一项卖出，市场共识目标价为 16.50 美元。该股票下跌 1.3%，报 4.58 美元，市值为 2.9573 亿美元。近期的内部交易和机构投资表明市场对该公司的兴趣日益增长，该公司专注于基于人工智能的药物开发</p>

<p>Immuneering Corporation (NASDAQ:IMRX - Get Free Report) saw a large growth in short interest during the month of December. As of December 31st, there was short interest totaling 10,924,303 shares, a growth of 43.1% from the December 15th total of 7,635,854 shares. Approximately 21.9% of the shares of the company are short sold. Based on an average daily volume of 1,780,211 shares, the short-interest ratio is currently 6.1 days. Based on an average daily volume of 1,780,211 shares, the short-interest ratio is currently 6.1 days. Approximately 21.9% of the shares of the company are short sold.</p>
<div class="lb-trans"><p>Immuneering Corporation (NASDAQ:IMRX - 获取免费报告) 在 12 月份的空头头寸大幅增长。截至 12 月 31 日，空头头寸总计为 10,924,303 股，比 12 月 15 日的 7635854 股增长了 43.1%。该公司的约 21.9% 的股份被做空。根据平均每日交易量 1,780,211 股，目前的空头头寸比率为 6.1 天。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>A number of equities research analysts recently weighed in on the company. HC Wainwright reissued a &#34;buy&#34; rating and set a $11.00 target price on shares of Immuneering in a research report on Tuesday, September 30th. Leerink Partnrs raised Immuneering to a &#34;strong-buy&#34; rating in a report on Friday, October 31st. Chardan Capital restated a &#34;buy&#34; rating and set a $20.00 price objective on shares of Immuneering in a research report on Thursday, November 13th. Mizuho set a $12.00 target price on Immuneering in a research note on Wednesday, October 29th. Finally, Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Immuneering in a research note on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $16.50.</p>
<div class="lb-trans"><p>一些股票研究分析师最近对该公司发表了看法。HC Wainwright 在 9 月 30 日的研究报告中重申了 “买入” 评级，并将 Immuneering 的目标价格设定为 11.00 美元。Leerink Partners 在 10 月 31 日的报告中将 Immuneering 的评级提升至 “强力买入”。Chardan Capital 在 11 月 13 日的研究报告中重申了 “买入” 评级，并将 Immuneering 的目标价格设定为 20.00 美元。瑞穗证券在 10 月 29 日的研究报告中将 Immuneering 的目标价格设定为 12.00 美元。最后，Weiss Ratings 在 12 月 29 日的研究报告中重申了对 Immuneering 的 “卖出（d-）” 评级。一位分析师给予该股票 “强力买入” 评级，六位分析师给予 “买入” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，该公司的共识评级为 “适度买入”，共识目标价格为 16.50 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on Immuneering</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 Immuneering 股票报告</strong></p>
</div><h2>Immuneering Trading Down 1.3%</h2>
<div class="lb-trans"><h2>Immuneering 股价下跌 1.3%</h2>
</div><p>IMRX stock traded down $0.06 during trading on Friday, hitting $4.58. 1,571,991 shares of the stock traded hands, compared to its average volume of 3,135,325. The stock has a market cap of $295.73 million, a price-to-earnings ratio of -2.57 and a beta of 0.48. Immuneering has a one year low of $1.10 and a one year high of $10.08. The company has a 50 day simple moving average of $6.37 and a 200 day simple moving average of $5.78.</p>
<div class="lb-trans"><p>IMRX 股票在周五交易中下跌 0.06 美元，报 4.58 美元。该股票交易了 1,571,991 股，而其平均交易量为 3,135,325 股。该公司的市值为 2.9573 亿美元，市盈率为-2.57，贝塔值为 0.48。Immuneering 的股价在过去一年中最低为 1.10 美元，最高为 10.08 美元。该公司的 50 日简单移动平均为 6.37 美元，200 日简单移动平均为 5.78 美元。</p>
</div><p>Immuneering (NASDAQ:IMRX - Get Free Report) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.01). As a group, analysts predict that Immuneering will post -1.86 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Immuneering (NASDAQ:IMRX - 获取免费报告) 最近在 11 月 12 日发布了季度财报。该公司报告每股收益为-0.38 美元，低于共识预期的-0.37 美元，差距为 0.01 美元。整体来看，分析师预测 Immuneering 在当前财政年度的每股收益为-1.86 美元。</p>
</div><h2>Insider Transactions at Immuneering</h2>
<div class="lb-trans"><h2>Immuneering 的内部交易</h2>
</div><p>In related news, Director Peter Feinberg acquired 20,000 shares of the company's stock in a transaction dated Monday, January 12th. The shares were bought at an average price of $4.35 per share, for a total transaction of $87,000.00. Following the acquisition, the director owned 135,441 shares in the company, valued at $589,168.35. This trade represents a 17.32% increase in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through the SEC website. In the last quarter, insiders have acquired 24,924 shares of company stock valued at $108,400. Company insiders own 22.90% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，董事 Peter Feinberg 在 1 月 12 日的交易中购买了 20,000 股该公司的股票。每股平均购买价格为 4.35 美元，总交易额为 87,000.00 美元。收购后，该董事在公司中持有 135,441 股，价值 589,168.35 美元。此交易代表其持股比例增加了 17.32%。该交易已在证券交易委员会的法律文件中披露，可通过 SEC 网站访问。在上个季度，内部人士购买了价值 108,400 美元的 24,924 股公司股票。公司内部人士持有该公司 22.90% 的股份。</p>
</div><h2>Institutional Trading of Immuneering</h2>
<div class="lb-trans"><h2>Immuneering 的机构交易</h2>
</div><p>Large investors have recently made changes to their positions in the business. Sanofi acquired a new position in shares of Immuneering during the third quarter valued at $18,960,000. Vanguard Group Inc. raised its holdings in Immuneering by 128.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,415,244 shares of the company's stock worth $16,907,000 after purchasing an additional 1,358,322 shares during the last quarter. Citadel Advisors LLC acquired a new position in Immuneering during the 3rd quarter valued at about $6,602,000. Blue Owl Capital Holdings LP bought a new position in shares of Immuneering in the 3rd quarter valued at about $3,850,000. Finally, Monashee Investment Management LLC acquired a new stake in shares of Immuneering during the 3rd quarter worth approximately $2,100,000. Institutional investors own 67.65% of the company's stock.</p>
<div class="lb-trans"><p>大型投资者最近对该公司的持仓进行了调整。赛诺菲在第三季度以 18,960,000 美元的估值收购了 Immuneering 的新股份。先锋集团在第三季度将其在 Immuneering 的持股增加了 128.5%。先锋集团目前拥有 2,415,244 股该公司的股票，价值 16,907,000 美元，此前在上个季度购买了 1,358,322 股。Citadel Advisors LLC 在第三季度以约 6,602,000 美元的估值收购了 Immuneering 的新股份。Blue Owl Capital Holdings LP 在第三季度以约 3,850,000 美元的估值购买了 Immuneering 的新股份。最后，Monashee Investment Management LLC 在第三季度以约 2,100,000 美元的估值收购了 Immuneering 的新股份。机构投资者持有该公司 67.65% 的股份。</p>
</div><h2>Immuneering Company Profile</h2>
<div class="lb-trans"><h2>Immuneering 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Immuneering Nasdaq: IMRX is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering's machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company's AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.</p>
<div class="lb-trans"><p>Immuneering Nasdaq: IMRX 是一家临床阶段的生物制药公司，利用人工智能和其专有的 RABIT（重新利用和加速生物技术工具）平台设计和优化小分子和肽类疗法。通过分析大规模生物医学数据集，Immuneering 的机器学习算法识别新型药物 - 靶点相互作用，重新利用现有药物框架并加速候选药物的选择。该公司的人工智能驱动方法旨在缩短开发时间并改善在高未满足医疗需求领域的治疗效果。</p>
</div><p>The company's lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.</p>
<div class="lb-trans"><p>该公司的主导项目 IRX-2 是一种小分子候选药物，目前正在进行针对疼痛性糖尿病周围神经病的第二阶段临床试验。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Immuneering</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>Executive Order 14330: Trump’s Biggest Yet</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Immuneering</li>
<li>Elon 将 SpaceX 上市！100 美元的首次公开募股机会！</li>
<li>家族信托如何帮助保护您的财富</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>执行命令 14330：特朗普最大的一次</li>
<li>新法律：国会批准数字美元的设立？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Immuneering Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元在 Immuneering 吗？</h2>
</div><p>Before you consider Immuneering, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Immuneering 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immuneering wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Immuneering 并不在名单上。</p>
</div><p>While Immuneering currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 Immuneering 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Immuneering Corporation（纳斯达克股票代码：IMRX）的空头头寸显著增长